Stories - Corcept Therapeutics

Stories and perspectives.

Featured Stories

We are Corcept.

Founding Corcept

Turning Pain into Purpose and Leaving her Mark: Rachel’s Journey with Ovarian Cancer

All Stories

Corcept to Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ASCO 2025

Press Release: April 23, 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Press Release: April 21, 2025

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Press Release: Mar 31, 2025

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Press Release: Mar 3, 2025

A Simple Test, A Life-Changing Diagnosis: The Cortisol Connection

Honoring Rosalyn Yalow, Ph.D.

Honoring Dr. LaSalle D. Leffall Jr.

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Press Release: Dec 30, 2024

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Press Release: Dec 16, 2024